Lynparza data shows survival and quality of life benefit

2 June 2017

Phase III data on Anglo-Swedish pharma major AstraZeneca’s (LSE: AZN) of Lynparza (olaparib) 300mg twice-daily tablet maintenance treatment shows that quality of life (QoL) is sustained alongside improved progression-free survival (PFS) in women with germline BRCA-mutated (gBRCAm), platinum-sensitive, relapsed serous ovarian cancer.

The SOLO-2 trial data presented at ASCO shows that on three separate rating scales, women receiving olaparib maintenance treatment reported similar QoL to those taking placebo. Significant ‘patient-centered benefits’ of olaparib versus placebo in quality-adjusted progression-free survival and time without symptoms of disease or toxicity were observed up to 27 months after randomization.

The strong benefit observed with Lynparza as an ovarian cancer maintenance therapy bolsters AstraZeneca against a competing PARP inhibitor from Tesaro (Nasdaq: TSRO). US personalized cancer therapy specialist Clovis Oncology (Nasdaq: CLVS) also has a rival with its recently-approved PARP inhibitor Rubraca (rucaparib).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK